 Proactive Investors USA & Canada |
Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma …
Washington Post Drugmaker Merck & Co. said Friday that third-quarter profit rose 2 percent as reduced spending on overhead offset lower sales due to new generic competition for its top-selling drug, Singulair. The maker of diabetes pill Januvia beat Wall Street's … Merck tops view, newer drugs cushion asthma drug blow Merck Q3 earnings edge up despite decline in sales Merck's Profit Rises 2.2% |
View full post on asthma – Google News